AU2021232524A1 - New method and compound for prostate cancer diagnosis - Google Patents

New method and compound for prostate cancer diagnosis Download PDF

Info

Publication number
AU2021232524A1
AU2021232524A1 AU2021232524A AU2021232524A AU2021232524A1 AU 2021232524 A1 AU2021232524 A1 AU 2021232524A1 AU 2021232524 A AU2021232524 A AU 2021232524A AU 2021232524 A AU2021232524 A AU 2021232524A AU 2021232524 A1 AU2021232524 A1 AU 2021232524A1
Authority
AU
Australia
Prior art keywords
cdr
seq
prostasomes
antigen binding
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021232524A
Other languages
English (en)
Inventor
Anders Larsson
Anders Waldenström
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosmedic Sweden AB
Original Assignee
Prosmedic Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosmedic Sweden AB filed Critical Prosmedic Sweden AB
Publication of AU2021232524A1 publication Critical patent/AU2021232524A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021232524A 2020-03-03 2021-03-01 New method and compound for prostate cancer diagnosis Pending AU2021232524A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20160712.4 2020-03-03
EP20160712.4A EP3875482A1 (en) 2020-03-03 2020-03-03 New method and compound for prostate cancer diagnosis
PCT/EP2021/055061 WO2021175788A1 (en) 2020-03-03 2021-03-01 New method and compound for prostate cancer diagnosis

Publications (1)

Publication Number Publication Date
AU2021232524A1 true AU2021232524A1 (en) 2022-09-29

Family

ID=69770502

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021232524A Pending AU2021232524A1 (en) 2020-03-03 2021-03-01 New method and compound for prostate cancer diagnosis

Country Status (7)

Country Link
US (1) US20230093265A1 (https=)
EP (2) EP3875482A1 (https=)
JP (1) JP7827630B2 (https=)
CN (1) CN115210256A (https=)
AU (1) AU2021232524A1 (https=)
CA (1) CA3168158A1 (https=)
WO (1) WO2021175788A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI131968B1 (en) * 2023-10-16 2026-03-17 Teknologian Tutkimuskeskus Vtt Oy ANTIBODY BINDINGS AS CANCER BIOMARKERS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9374198A (en) * 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
SE535084C2 (sv) * 2010-04-16 2012-04-10 Prostasom Handelsbolag Förfarande för cancerdiagnos
US9029086B2 (en) * 2012-01-26 2015-05-12 Masood Kamali Moghaddam Detection of single and multimodal analytes

Also Published As

Publication number Publication date
US20230093265A1 (en) 2023-03-23
EP3875482A1 (en) 2021-09-08
WO2021175788A1 (en) 2021-09-10
JP7827630B2 (ja) 2026-03-10
CN115210256A (zh) 2022-10-18
EP4114853A1 (en) 2023-01-11
CA3168158A1 (en) 2021-09-10
JP2023516705A (ja) 2023-04-20

Similar Documents

Publication Publication Date Title
JP6180931B2 (ja) 癌の診断および／または予後のための新規な抗体
CN110651190A (zh) 用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
AU2018378971A1 (en) Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
RU2693006C2 (ru) Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы
JP7156622B2 (ja) 前立腺癌検出のための組成物と方法
US20160349263A1 (en) Cell surface prostate cancer antigen for diagnosis
AU2017204683B2 (en) Compositions and methods for assessing the risk of cancer occurrence
KR102795552B1 (ko) 트립토파닐-티알엔에이 합성효소 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP7827630B2 (ja) 前立腺がんを診断するための新規な方法と化合物
US11231423B2 (en) Method and kit for the detection of biliary tract cancer
JPWO2018135653A1 (ja) 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出
CN115104029A (zh) 用于检测和监测全身性炎症的非侵入性测定法
CN111303289B (zh) 抗人Tn型糖基化MUC1抗体及其用途
JP6797107B2 (ja) 膵臓機能異常の検出方法及び検出用キット
TWI869740B (zh) 一種體外檢測ｓＴＮＦＲ２蛋白濃度的方法及其檢測試劑和檢測試劑盒
WO2026074330A1 (en) Antibodies and diagnostic methods for detecting bag3 protein in clinical samples
WO2022202826A1 (ja) 悪性膵嚢胞性腫瘍の判定補助方法及び判定補助用キット
CA3009768C (en) Compositions and methods for assessing the risk of cancer occurrence
WO2012077643A1 (ja) ｃｏｆｉｌｉｎ１タンパク質の免疫学的測定方法
HK1262633B (zh) 用於评估癌症发生的风险的组合物和方法
HK1225791B (en) Cell surface prostate cancer antigen for diagnosis